Oxford BioMedica (LON:OXB)‘s stock had its “buy” rating reiterated by Peel Hunt in a research report issued on Friday, ThisIsMoney.Co.Uk reports.
A number of other research firms have also recently weighed in on OXB. Liberum Capital reaffirmed a “buy” rating on shares of Oxford BioMedica in a research report on Tuesday, July 21st. Jefferies Financial Group raised their price target on shares of Oxford BioMedica from GBX 700 ($8.61) to GBX 730 ($8.98) and gave the company a “hold” rating in a research report on Thursday, May 14th.
LON:OXB opened at GBX 817 ($10.05) on Friday. The company has a debt-to-equity ratio of 11.09, a quick ratio of 1.82 and a current ratio of 1.97. The stock has a market capitalization of $670.32 million and a P/E ratio of -36.97. The company has a 50 day moving average price of GBX 790.50 and a 200 day moving average price of GBX 688.76. Oxford BioMedica has a fifty-two week low of GBX 7 ($0.09) and a fifty-two week high of GBX 890 ($10.95).
In other news, insider Stuart Paynter acquired 1,472 shares of the firm’s stock in a transaction dated Wednesday, May 6th. The stock was acquired at an average cost of GBX 675 ($8.31) per share, with a total value of £9,936 ($12,227.42). Also, insider Andrew Heath sold 1,000 shares of Oxford BioMedica stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of GBX 704 ($8.66), for a total transaction of £7,040 ($8,663.55). Insiders acquired a total of 91,271 shares of company stock valued at $73,523,817 in the last three months.
About Oxford BioMedica
Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments.
Further Reading: Gross Domestic Product (GDP)
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.